Horizon Pharma | HZNP - Beneficio Bruto En Ventas



Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 10.47B 605M 2025-09
ALKERMES USD 338.34M 72.51M 2025-12
Amgen USD 6.48B 307M 2025-09
AstraZeneca USD 12.39B 5M 2025-12
Bausch Health Companies USD 1.93B 165M 2025-09
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Cara Therapeutics USD 2.57M 1.11M 2025-03
Coherus Biosciences USD 8.7M 853K 2025-12
Eli Lilly USD 14.59B 1.48B 2025-09
Merck USD 13.42B 431M 2025-09
Novartis USD 10.25B 570M 2025-12
Pacira USD 142.25M 11.34M 2025-12
Perrigo USD 362.2M 14.9M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
Prestige Brands USD 157.37M 5.79M 2025-12
Supernus Pharmaceuticals USD 164.04M 15.23M 2025-12
Takeda JPY 790.55B 262.97B 2025-12
Xeris Pharmaceuticals USD 72.15M 8.77M 2025-12
Zoetis USD 1.64B 73M 2025-12